aluates Reports

$ 0.0

Automative

Global GalNAc-siRNA Conjugates Drug Market Research Report 2024

Published Date: November 2024

Report Code: QYRE-Auto-24I18169

BUY CHAPTERS

Global GalNAc-siRNA Conjugates Drug Market Research Report 2024

Code: QYRE-Auto-24I18169

Report

November 2024

Pages:79

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

LNP

Suzhou Ribo Life Science Co.,Ltd.

Sirnaomics

Alnylam Pharmaceuticals

Arrowhead

Novo Nordisk (Dicerna)

Silence Therapeutics

Arbutus

Novartis

Hitgen (Leaderna Therapeutics Ltd.)

GalNAc-siRNA Conjugates Drug Market

GalNAc-siRNA conjugates are polysaccharide-siRNA monoconjugates formed by covalently fixing N-acetylated galactosamine (GalNAc) in a trivalent state to the 3' end of the right strand of siRNA of different sequences. GalNAc is a targeting ligand of sialic acid receptor (ASGPR) with high affinity and rapid internalization to liver surface cells, enabling such siRNA conjugates to specifically bind to membrane proteins and enter the cytosol. GalNAc conjugation modification is currently the most commonly used small nucleic acid drug delivery system and has excellent potential in the treatment of liver-related diseases involving gene overexpression. GalNAc conjugates have largely replaced lipid nanoparticles (LNP) for siRNA delivery for liver-targeted diseases. Therefore, drugs based on GalNAc-siRNA conjugates have bright application prospects in cardiovascular diseases, metabolic diseases, and neurological diseases.

The global GalNAc-siRNA Conjugates Drug market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.

North American market for GalNAc-siRNA Conjugates Drug is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Asia-Pacific market for GalNAc-siRNA Conjugates Drug is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The global market for GalNAc-siRNA Conjugates Drug in Cardiovascular Diseases is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The major global companies of GalNAc-siRNA Conjugates Drug include Suzhou Ribo Life Science Co., Ltd, Sirnaomics, Alnylam Pharmaceuticals, Arrowhead, Novo Nordisk (Dicerna), Silence Therapeutics, Arbutus, Novartis, Hitgen (Leaderna Therapeutics Ltd.), etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

This report aims to provide a comprehensive presentation of the global market for GalNAc-siRNA Conjugates Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding GalNAc-siRNA Conjugates Drug.

The GalNAc-siRNA Conjugates Drug market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global GalNAc-siRNA Conjugates Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the GalNAc-siRNA Conjugates Drug companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of GalNAc-siRNA Conjugates Drug Market Report

Report Metric	Details
Report Name	GalNAc-siRNA Conjugates Drug Market
Segment by Type	Listing Clinical Trial
Segment by Application	Cardiovascular Diseases Metabolic Diseases Neurological Diseases Other
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Suzhou Ribo Life Science Co., Ltd, Sirnaomics, Alnylam Pharmaceuticals, Arrowhead, Novo Nordisk (Dicerna), Silence Therapeutics, Arbutus, Novartis, Hitgen (Leaderna Therapeutics Ltd.)
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of GalNAc-siRNA Conjugates Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the GalNAc-siRNA Conjugates Drug Market report?

Ans: The main players in the GalNAc-siRNA Conjugates Drug Market are Suzhou Ribo Life Science Co., Ltd, Sirnaomics, Alnylam Pharmaceuticals, Arrowhead, Novo Nordisk (Dicerna), Silence Therapeutics, Arbutus, Novartis, Hitgen (Leaderna Therapeutics Ltd.)

What are the Application segmentation covered in the GalNAc-siRNA Conjugates Drug Market report?

Ans: The Applications covered in the GalNAc-siRNA Conjugates Drug Market report are Cardiovascular Diseases, Metabolic Diseases, Neurological Diseases, Other

What are the Type segmentation covered in the GalNAc-siRNA Conjugates Drug Market report?

Ans: The Types covered in the GalNAc-siRNA Conjugates Drug Market report are Listing, Clinical Trial

Recommended Reports

Nucleic Acid Therapeutics

Drug Conjugate Markets

Gene And RNA Therapies

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global GalNAc-siRNA Conjugates Drug Market Size Growth Rate by Type: 2019 VS 2023 VS 2030

1.2.2 Listing

1.2.3 Clinical Trial

1.3 Market by Application

1.3.1 Global GalNAc-siRNA Conjugates Drug Market Growth by Application: 2019 VS 2023 VS 2030

1.3.2 Cardiovascular Diseases

1.3.3 Metabolic Diseases

1.3.4 Neurological Diseases

1.3.5 Other

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global GalNAc-siRNA Conjugates Drug Market Perspective (2019-2030)

2.2 Global GalNAc-siRNA Conjugates Drug Growth Trends by Region

2.2.1 Global GalNAc-siRNA Conjugates Drug Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 GalNAc-siRNA Conjugates Drug Historic Market Size by Region (2019-2024)

2.2.3 GalNAc-siRNA Conjugates Drug Forecasted Market Size by Region (2025-2030)

2.3 GalNAc-siRNA Conjugates Drug Market Dynamics

2.3.1 GalNAc-siRNA Conjugates Drug Industry Trends

2.3.2 GalNAc-siRNA Conjugates Drug Market Drivers

2.3.3 GalNAc-siRNA Conjugates Drug Market Challenges

2.3.4 GalNAc-siRNA Conjugates Drug Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top GalNAc-siRNA Conjugates Drug Players by Revenue

3.1.1 Global Top GalNAc-siRNA Conjugates Drug Players by Revenue (2019-2024)

3.1.2 Global GalNAc-siRNA Conjugates Drug Revenue Market Share by Players (2019-2024)

3.2 Global GalNAc-siRNA Conjugates Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by GalNAc-siRNA Conjugates Drug Revenue

3.4 Global GalNAc-siRNA Conjugates Drug Market Concentration Ratio

3.4.1 Global GalNAc-siRNA Conjugates Drug Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by GalNAc-siRNA Conjugates Drug Revenue in 2023

3.5 Global Key Players of GalNAc-siRNA Conjugates Drug Head office and Area Served

3.6 Global Key Players of GalNAc-siRNA Conjugates Drug, Product and Application

3.7 Global Key Players of GalNAc-siRNA Conjugates Drug, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 GalNAc-siRNA Conjugates Drug Breakdown Data by Type

4.1 Global GalNAc-siRNA Conjugates Drug Historic Market Size by Type (2019-2024)

4.2 Global GalNAc-siRNA Conjugates Drug Forecasted Market Size by Type (2025-2030)

5 GalNAc-siRNA Conjugates Drug Breakdown Data by Application

5.1 Global GalNAc-siRNA Conjugates Drug Historic Market Size by Application (2019-2024)

5.2 Global GalNAc-siRNA Conjugates Drug Forecasted Market Size by Application (2025-2030)

6 North America

6.1 North America GalNAc-siRNA Conjugates Drug Market Size (2019-2030)

6.2 North America GalNAc-siRNA Conjugates Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030

6.3 North America GalNAc-siRNA Conjugates Drug Market Size by Country (2019-2024)

6.4 North America GalNAc-siRNA Conjugates Drug Market Size by Country (2025-2030)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe GalNAc-siRNA Conjugates Drug Market Size (2019-2030)

7.2 Europe GalNAc-siRNA Conjugates Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030

7.3 Europe GalNAc-siRNA Conjugates Drug Market Size by Country (2019-2024)

7.4 Europe GalNAc-siRNA Conjugates Drug Market Size by Country (2025-2030)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific GalNAc-siRNA Conjugates Drug Market Size (2019-2030)

8.2 Asia-Pacific GalNAc-siRNA Conjugates Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030

8.3 Asia-Pacific GalNAc-siRNA Conjugates Drug Market Size by Region (2019-2024)

8.4 Asia-Pacific GalNAc-siRNA Conjugates Drug Market Size by Region (2025-2030)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America GalNAc-siRNA Conjugates Drug Market Size (2019-2030)

9.2 Latin America GalNAc-siRNA Conjugates Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030

9.3 Latin America GalNAc-siRNA Conjugates Drug Market Size by Country (2019-2024)

9.4 Latin America GalNAc-siRNA Conjugates Drug Market Size by Country (2025-2030)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa GalNAc-siRNA Conjugates Drug Market Size (2019-2030)

10.2 Middle East & Africa GalNAc-siRNA Conjugates Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030

10.3 Middle East & Africa GalNAc-siRNA Conjugates Drug Market Size by Country (2019-2024)

10.4 Middle East & Africa GalNAc-siRNA Conjugates Drug Market Size by Country (2025-2030)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Suzhou Ribo Life Science Co., Ltd

11.1.1 Suzhou Ribo Life Science Co., Ltd Company Details

11.1.2 Suzhou Ribo Life Science Co., Ltd Business Overview

11.1.3 Suzhou Ribo Life Science Co., Ltd GalNAc-siRNA Conjugates Drug Introduction

11.1.4 Suzhou Ribo Life Science Co., Ltd Revenue in GalNAc-siRNA Conjugates Drug Business (2019-2024)

11.1.5 Suzhou Ribo Life Science Co., Ltd Recent Development

11.2 Sirnaomics

11.2.1 Sirnaomics Company Details

11.2.2 Sirnaomics Business Overview

11.2.3 Sirnaomics GalNAc-siRNA Conjugates Drug Introduction

11.2.4 Sirnaomics Revenue in GalNAc-siRNA Conjugates Drug Business (2019-2024)

11.2.5 Sirnaomics Recent Development

11.3 Alnylam Pharmaceuticals

11.3.1 Alnylam Pharmaceuticals Company Details

11.3.2 Alnylam Pharmaceuticals Business Overview

11.3.3 Alnylam Pharmaceuticals GalNAc-siRNA Conjugates Drug Introduction

11.3.4 Alnylam Pharmaceuticals Revenue in GalNAc-siRNA Conjugates Drug Business (2019-2024)

11.3.5 Alnylam Pharmaceuticals Recent Development

11.4 Arrowhead

11.4.1 Arrowhead Company Details

11.4.2 Arrowhead Business Overview

11.4.3 Arrowhead GalNAc-siRNA Conjugates Drug Introduction

11.4.4 Arrowhead Revenue in GalNAc-siRNA Conjugates Drug Business (2019-2024)

11.4.5 Arrowhead Recent Development

11.5 Novo Nordisk (Dicerna)

11.5.1 Novo Nordisk (Dicerna) Company Details

11.5.2 Novo Nordisk (Dicerna) Business Overview

11.5.3 Novo Nordisk (Dicerna) GalNAc-siRNA Conjugates Drug Introduction

11.5.4 Novo Nordisk (Dicerna) Revenue in GalNAc-siRNA Conjugates Drug Business (2019-2024)

11.5.5 Novo Nordisk (Dicerna) Recent Development

11.6 Silence Therapeutics

11.6.1 Silence Therapeutics Company Details

11.6.2 Silence Therapeutics Business Overview

11.6.3 Silence Therapeutics GalNAc-siRNA Conjugates Drug Introduction

11.6.4 Silence Therapeutics Revenue in GalNAc-siRNA Conjugates Drug Business (2019-2024)

11.6.5 Silence Therapeutics Recent Development

11.7 Arbutus

11.7.1 Arbutus Company Details

11.7.2 Arbutus Business Overview

11.7.3 Arbutus GalNAc-siRNA Conjugates Drug Introduction

11.7.4 Arbutus Revenue in GalNAc-siRNA Conjugates Drug Business (2019-2024)

11.7.5 Arbutus Recent Development

11.8 Novartis

11.8.1 Novartis Company Details

11.8.2 Novartis Business Overview

11.8.3 Novartis GalNAc-siRNA Conjugates Drug Introduction

11.8.4 Novartis Revenue in GalNAc-siRNA Conjugates Drug Business (2019-2024)

11.8.5 Novartis Recent Development

11.9 Hitgen (Leaderna Therapeutics Ltd.)

11.9.1 Hitgen (Leaderna Therapeutics Ltd.) Company Details

11.9.2 Hitgen (Leaderna Therapeutics Ltd.) Business Overview

11.9.3 Hitgen (Leaderna Therapeutics Ltd.) GalNAc-siRNA Conjugates Drug Introduction

11.9.4 Hitgen (Leaderna Therapeutics Ltd.) Revenue in GalNAc-siRNA Conjugates Drug Business (2019-2024)

11.9.5 Hitgen (Leaderna Therapeutics Ltd.) Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

LNP

Suzhou Ribo Life Science Co.,Ltd.

Sirnaomics

Alnylam Pharmaceuticals

Arrowhead

Novo Nordisk (Dicerna)

Silence Therapeutics

Arbutus

Novartis

Hitgen (Leaderna Therapeutics Ltd.)

List of Tables

Table 1. Global GalNAc-siRNA Conjugates Drug Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030

Table 2. Key Players of Listing

Table 3. Key Players of Clinical Trial

Table 4. Global GalNAc-siRNA Conjugates Drug Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030

Table 5. Global GalNAc-siRNA Conjugates Drug Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 6. Global GalNAc-siRNA Conjugates Drug Market Size by Region (2019-2024) & (US$ Million)

Table 7. Global GalNAc-siRNA Conjugates Drug Market Share by Region (2019-2024)

Table 8. Global GalNAc-siRNA Conjugates Drug Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 9. Global GalNAc-siRNA Conjugates Drug Market Share by Region (2025-2030)

Table 10. GalNAc-siRNA Conjugates Drug Market Trends

Table 11. GalNAc-siRNA Conjugates Drug Market Drivers

Table 12. GalNAc-siRNA Conjugates Drug Market Challenges

Table 13. GalNAc-siRNA Conjugates Drug Market Restraints

Table 14. Global GalNAc-siRNA Conjugates Drug Revenue by Players (2019-2024) & (US$ Million)

Table 15. Global GalNAc-siRNA Conjugates Drug Market Share by Players (2019-2024)

Table 16. Global Top GalNAc-siRNA Conjugates Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in GalNAc-siRNA Conjugates Drug as of 2023)

Table 17. Ranking of Global Top GalNAc-siRNA Conjugates Drug Companies by Revenue (US$ Million) in 2023

Table 18. Global 5 Largest Players Market Share by GalNAc-siRNA Conjugates Drug Revenue (CR5 and HHI) & (2019-2024)

Table 19. Global Key Players of GalNAc-siRNA Conjugates Drug, Headquarters and Area Served

Table 20. Global Key Players of GalNAc-siRNA Conjugates Drug, Product and Application

Table 21. Global Key Players of GalNAc-siRNA Conjugates Drug, Date of Enter into This Industry

Table 22. Mergers & Acquisitions, Expansion Plans

Table 23. Global GalNAc-siRNA Conjugates Drug Market Size by Type (2019-2024) & (US$ Million)

Table 24. Global GalNAc-siRNA Conjugates Drug Revenue Market Share by Type (2019-2024)

Table 25. Global GalNAc-siRNA Conjugates Drug Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 26. Global GalNAc-siRNA Conjugates Drug Revenue Market Share by Type (2025-2030)

Table 27. Global GalNAc-siRNA Conjugates Drug Market Size by Application (2019-2024) & (US$ Million)

Table 28. Global GalNAc-siRNA Conjugates Drug Revenue Market Share by Application (2019-2024)

Table 29. Global GalNAc-siRNA Conjugates Drug Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 30. Global GalNAc-siRNA Conjugates Drug Revenue Market Share by Application (2025-2030)

Table 31. North America GalNAc-siRNA Conjugates Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 32. North America GalNAc-siRNA Conjugates Drug Market Size by Country (2019-2024) & (US$ Million)

Table 33. North America GalNAc-siRNA Conjugates Drug Market Size by Country (2025-2030) & (US$ Million)

Table 34. Europe GalNAc-siRNA Conjugates Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 35. Europe GalNAc-siRNA Conjugates Drug Market Size by Country (2019-2024) & (US$ Million)

Table 36. Europe GalNAc-siRNA Conjugates Drug Market Size by Country (2025-2030) & (US$ Million)

Table 37. Asia-Pacific GalNAc-siRNA Conjugates Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 38. Asia-Pacific GalNAc-siRNA Conjugates Drug Market Size by Region (2019-2024) & (US$ Million)

Table 39. Asia-Pacific GalNAc-siRNA Conjugates Drug Market Size by Region (2025-2030) & (US$ Million)

Table 40. Latin America GalNAc-siRNA Conjugates Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 41. Latin America GalNAc-siRNA Conjugates Drug Market Size by Country (2019-2024) & (US$ Million)

Table 42. Latin America GalNAc-siRNA Conjugates Drug Market Size by Country (2025-2030) & (US$ Million)

Table 43. Middle East & Africa GalNAc-siRNA Conjugates Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 44. Middle East & Africa GalNAc-siRNA Conjugates Drug Market Size by Country (2019-2024) & (US$ Million)

Table 45. Middle East & Africa GalNAc-siRNA Conjugates Drug Market Size by Country (2025-2030) & (US$ Million)

Table 46. Suzhou Ribo Life Science Co., Ltd Company Details

Table 47. Suzhou Ribo Life Science Co., Ltd Business Overview

Table 48. Suzhou Ribo Life Science Co., Ltd GalNAc-siRNA Conjugates Drug Product

Table 49. Suzhou Ribo Life Science Co., Ltd Revenue in GalNAc-siRNA Conjugates Drug Business (2019-2024) & (US$ Million)

Table 50. Suzhou Ribo Life Science Co., Ltd Recent Development

Table 51. Sirnaomics Company Details

Table 52. Sirnaomics Business Overview

Table 53. Sirnaomics GalNAc-siRNA Conjugates Drug Product

Table 54. Sirnaomics Revenue in GalNAc-siRNA Conjugates Drug Business (2019-2024) & (US$ Million)

Table 55. Sirnaomics Recent Development

Table 56. Alnylam Pharmaceuticals Company Details

Table 57. Alnylam Pharmaceuticals Business Overview

Table 58. Alnylam Pharmaceuticals GalNAc-siRNA Conjugates Drug Product

Table 59. Alnylam Pharmaceuticals Revenue in GalNAc-siRNA Conjugates Drug Business (2019-2024) & (US$ Million)

Table 60. Alnylam Pharmaceuticals Recent Development

Table 61. Arrowhead Company Details

Table 62. Arrowhead Business Overview

Table 63. Arrowhead GalNAc-siRNA Conjugates Drug Product

Table 64. Arrowhead Revenue in GalNAc-siRNA Conjugates Drug Business (2019-2024) & (US$ Million)

Table 65. Arrowhead Recent Development

Table 66. Novo Nordisk (Dicerna) Company Details

Table 67. Novo Nordisk (Dicerna) Business Overview

Table 68. Novo Nordisk (Dicerna) GalNAc-siRNA Conjugates Drug Product

Table 69. Novo Nordisk (Dicerna) Revenue in GalNAc-siRNA Conjugates Drug Business (2019-2024) & (US$ Million)

Table 70. Novo Nordisk (Dicerna) Recent Development

Table 71. Silence Therapeutics Company Details

Table 72. Silence Therapeutics Business Overview

Table 73. Silence Therapeutics GalNAc-siRNA Conjugates Drug Product

Table 74. Silence Therapeutics Revenue in GalNAc-siRNA Conjugates Drug Business (2019-2024) & (US$ Million)

Table 75. Silence Therapeutics Recent Development

Table 76. Arbutus Company Details

Table 77. Arbutus Business Overview

Table 78. Arbutus GalNAc-siRNA Conjugates Drug Product

Table 79. Arbutus Revenue in GalNAc-siRNA Conjugates Drug Business (2019-2024) & (US$ Million)

Table 80. Arbutus Recent Development

Table 81. Novartis Company Details

Table 82. Novartis Business Overview

Table 83. Novartis GalNAc-siRNA Conjugates Drug Product

Table 84. Novartis Revenue in GalNAc-siRNA Conjugates Drug Business (2019-2024) & (US$ Million)

Table 85. Novartis Recent Development

Table 86. Hitgen (Leaderna Therapeutics Ltd.) Company Details

Table 87. Hitgen (Leaderna Therapeutics Ltd.) Business Overview

Table 88. Hitgen (Leaderna Therapeutics Ltd.) GalNAc-siRNA Conjugates Drug Product

Table 89. Hitgen (Leaderna Therapeutics Ltd.) Revenue in GalNAc-siRNA Conjugates Drug Business (2019-2024) & (US$ Million)

Table 90. Hitgen (Leaderna Therapeutics Ltd.) Recent Development

Table 91. Research Programs/Design for This Report

Table 92. Key Data Information from Secondary Sources

Table 93. Key Data Information from Primary Sources

Table 94. Authors List of This Report

List of Figures

Figure 1. GalNAc-siRNA Conjugates Drug Picture

Figure 2. Global GalNAc-siRNA Conjugates Drug Market Size Comparison by Type (2024-2030) & (US$ Million)

Figure 3. Global GalNAc-siRNA Conjugates Drug Market Share by Type: 2023 VS 2030

Figure 4. Listing Features

Figure 5. Clinical Trial Features

Figure 6. Global GalNAc-siRNA Conjugates Drug Market Size by Application (2024-2030) & (US$ Million)

Figure 7. Global GalNAc-siRNA Conjugates Drug Market Share by Application: 2023 VS 2030

Figure 8. Cardiovascular Diseases Case Studies

Figure 9. Metabolic Diseases Case Studies

Figure 10. Neurological Diseases Case Studies

Figure 11. Other Case Studies

Figure 12. GalNAc-siRNA Conjugates Drug Report Years Considered

Figure 13. Global GalNAc-siRNA Conjugates Drug Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 14. Global GalNAc-siRNA Conjugates Drug Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 15. Global GalNAc-siRNA Conjugates Drug Market Share by Region: 2023 VS 2030

Figure 16. Global GalNAc-siRNA Conjugates Drug Market Share by Players in 2023

Figure 17. Global Top GalNAc-siRNA Conjugates Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in GalNAc-siRNA Conjugates Drug as of 2023)

Figure 18. The Top 10 and 5 Players Market Share by GalNAc-siRNA Conjugates Drug Revenue in 2023

Figure 19. North America GalNAc-siRNA Conjugates Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 20. North America GalNAc-siRNA Conjugates Drug Market Share by Country (2019-2030)

Figure 21. United States GalNAc-siRNA Conjugates Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 22. Canada GalNAc-siRNA Conjugates Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 23. Europe GalNAc-siRNA Conjugates Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 24. Europe GalNAc-siRNA Conjugates Drug Market Share by Country (2019-2030)

Figure 25. Germany GalNAc-siRNA Conjugates Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 26. France GalNAc-siRNA Conjugates Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 27. U.K. GalNAc-siRNA Conjugates Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 28. Italy GalNAc-siRNA Conjugates Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 29. Russia GalNAc-siRNA Conjugates Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 30. Nordic Countries GalNAc-siRNA Conjugates Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 31. Asia-Pacific GalNAc-siRNA Conjugates Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 32. Asia-Pacific GalNAc-siRNA Conjugates Drug Market Share by Region (2019-2030)

Figure 33. China GalNAc-siRNA Conjugates Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 34. Japan GalNAc-siRNA Conjugates Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 35. South Korea GalNAc-siRNA Conjugates Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 36. Southeast Asia GalNAc-siRNA Conjugates Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 37. India GalNAc-siRNA Conjugates Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 38. Australia GalNAc-siRNA Conjugates Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 39. Latin America GalNAc-siRNA Conjugates Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 40. Latin America GalNAc-siRNA Conjugates Drug Market Share by Country (2019-2030)

Figure 41. Mexico GalNAc-siRNA Conjugates Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 42. Brazil GalNAc-siRNA Conjugates Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 43. Middle East & Africa GalNAc-siRNA Conjugates Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 44. Middle East & Africa GalNAc-siRNA Conjugates Drug Market Share by Country (2019-2030)

Figure 45. Turkey GalNAc-siRNA Conjugates Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 46. Saudi Arabia GalNAc-siRNA Conjugates Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 47. UAE GalNAc-siRNA Conjugates Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 48. Suzhou Ribo Life Science Co., Ltd Revenue Growth Rate in GalNAc-siRNA Conjugates Drug Business (2019-2024)

Figure 49. Sirnaomics Revenue Growth Rate in GalNAc-siRNA Conjugates Drug Business (2019-2024)

Figure 50. Alnylam Pharmaceuticals Revenue Growth Rate in GalNAc-siRNA Conjugates Drug Business (2019-2024)

Figure 51. Arrowhead Revenue Growth Rate in GalNAc-siRNA Conjugates Drug Business (2019-2024)

Figure 52. Novo Nordisk (Dicerna) Revenue Growth Rate in GalNAc-siRNA Conjugates Drug Business (2019-2024)

Figure 53. Silence Therapeutics Revenue Growth Rate in GalNAc-siRNA Conjugates Drug Business (2019-2024)

Figure 54. Arbutus Revenue Growth Rate in GalNAc-siRNA Conjugates Drug Business (2019-2024)

Figure 55. Novartis Revenue Growth Rate in GalNAc-siRNA Conjugates Drug Business (2019-2024)

Figure 56. Hitgen (Leaderna Therapeutics Ltd.) Revenue Growth Rate in GalNAc-siRNA Conjugates Drug Business (2019-2024)

Figure 57. Bottom-up and Top-down Approaches for This Report

Figure 58. Data Triangulation

Figure 59. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global GalNAc Oligonucleotide Conjugates Market Research Report 2024

Global GalNAc Delivery Technology Market Research Report 2024

Global GalNAc ASO Conjugates Market Research Report 2024

Global GalNAc based Drug Market Research Report 2024

Global GalNAc and GalNAc Derivatives Market Research Report 2024

Global GalNac Conjugates Market Research Report 2024

Global siRNA Conjugates Market Research Report 2024

Global Small Interfering RNA siRNA Therapeutics Market Insights Forecast to 2030

Global mRNA Delivery System Market Research Report 2024

Global Targeted SSTR Radionuclide Drug Conjugates Market Research Report 2024

Global Oligonucleotide Bioconjugation Service Market Research Report 2024

Global RNA Interference RNAi Based Therapeutics Market Research Report 2024

Global PNA Conjugates Market Research Report 2024

Global Antibody Oligonucleotide Conjugates AOC Drug Market Research Report 2024

Global Aptamer Drug Conjugates ApDC Market Research Report 2024

Global Nucleic Acid Drugs Market Research Report 2025

Global Low Molecular Weight Nucleic Acid Drugs Market Research Report 2025

Global Small Interfering RNA siRNA based Therapeutics Market Research Report 2024

Global Antibody oligonucleotide Conjugates AOCs Market Research Report 2024

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions